We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDPH
RNS Number : 7795O
Dechra Pharmaceuticals PLC
09 November 2016
9 November 2016
Dechra(R) Pharmaceuticals PLC
(Dechra, Company or the Group)
Board Appointment
Appointment of Non-Executive Director
Dechra is pleased to announce that Lawson Macartney has been appointed to the Board as Non-Executive Director with effect from 1 December 2016.
Dr Macartney, a qualified veterinarian, is Chairman of Viking Therapeutics Inc., a developer of novel therapeutics for patients suffering from metabolic and endocrine disorders, and an adviser to several biopharmaceutical companies and life science consultancies. Prior to this, Dr Macartney was President and CEO of Ambrx Inc., Senior Vice President and Head of Emerging Business at Shire AG, and held various senior, global commercial, sales, marketing and strategy roles at GlaxoSmithKline plc.
Ian Page, Chief Executive Officer, Dechra Pharmaceuticals said:
"We are delighted to welcome Lawson to the Board and we look forward to working with him. Lawson's 30 years of experience gained in the global pharmaceutical industry will bring further knowledge and expertise of product development to the Board."
There are no other disclosures to be made in respect of Lawson Macartney, pursuant to Listing Rule 9.6.13R.
Enquiries to: Dechra Pharmaceuticals PLC Ian Page, Chief Executive Officer Office: +44 (0) 1606 814 730 e-mail: corporate.enquiries@dechra.com TooleyStreet Communications Ltd Fiona Tooley, Director Mobile: +44 (0) 7785 703 523 e-mail: fiona@tooleystreet.com
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
For more information please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFSDFLUFMSEIF
(END) Dow Jones Newswires
November 09, 2016 09:54 ET (14:54 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
